124 related articles for article (PubMed ID: 11125029)
1. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
Sissi C; Moro S; Richter S; Gatto B; Menta E; Spinelli S; Krapcho AP; Zunino F; Palumbo M
Mol Pharmacol; 2001 Jan; 59(1):96-103. PubMed ID: 11125029
[TBL] [Abstract][Full Text] [Related]
2. A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts.
Supino R; Polizzi D; Pavesi R; Pratesi G; Guano F; Capranico G; Palumbo M; Sissi C; Richter S; Beggiolin G; Menta E; Pezzoni G; Spinelli S; Torriani D; Carenini N; Dal Bo L; Facchinetti F; Tortoreto M; Zunino F
Oncology; 2001; 61(3):234-42. PubMed ID: 11574780
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
[TBL] [Abstract][Full Text] [Related]
4. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
Sissi C; Capranico G; Menta E; Palumbo M
Mol Pharmacol; 1996 Oct; 50(4):838-45. PubMed ID: 8863828
[TBL] [Abstract][Full Text] [Related]
5. Antitumor AZA-anthrapyrazoles: biophysical and biochemical studies on 8- and 9-aza regioisomers.
Sissi C; Leo E; Moro S; Capranico G; Mancia A; Menta E; Krapcho AP; Palumbo M
Biochem Pharmacol; 2004 Feb; 67(4):631-42. PubMed ID: 14757163
[TBL] [Abstract][Full Text] [Related]
6. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity.
Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M
J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632
[TBL] [Abstract][Full Text] [Related]
7. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.
Liang H; Wu X; Guziec LJ; Guziec FS; Larson KK; Lang J; Yalowich JC; Hasinoff BB
J Chem Inf Model; 2006; 46(4):1827-35. PubMed ID: 16859314
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC
Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones.
de Isabella P; Palumbo M; Sissi C; Carenini N; Capranico G; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC; Zunino F
Biochem Pharmacol; 1997 Jan; 53(2):161-9. PubMed ID: 9037248
[TBL] [Abstract][Full Text] [Related]
10. Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: effects of the relative positioning of the side chains.
Sissi C; Moro S; Zagotto G; Ellis M; Krapcho AP; Menta E; Palumbo M
Anticancer Drug Des; 1999 Jun; 14(3):265-74. PubMed ID: 10500501
[TBL] [Abstract][Full Text] [Related]
11. DNA-binding preferences of bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning.
Sissi C; Bolgan L; Moro S; Zagotto G; Bailly C; Menta E; Capranico G; Palumbo M
Mol Pharmacol; 1998 Dec; 54(6):1036-45. PubMed ID: 9855632
[TBL] [Abstract][Full Text] [Related]
12. Amido analogs of mitoxantrone: physico-chemical properties, molecular modeling, cellular effects and antineoplastic potential.
Zagotto G; Moro S; Uriarte E; Ferrazzi E; Palù G; Palumbo M
Anticancer Drug Des; 1997 Mar; 12(2):99-112. PubMed ID: 9113065
[TBL] [Abstract][Full Text] [Related]
13. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
14. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
15. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones.
Hazlehurst LA; Krapcho AP; Hacker MP
Cancer Lett; 1995 May; 91(1):115-24. PubMed ID: 7750086
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of site-specific topoisomerase II-mediated DNA cleavage by an N-methylpyrrolecarboxamide-anilinoacridine conjugate: relation to DNA binding.
Fossé P; René B; Saucier JM; Hénichart JP; Waring MJ; Colson P; Houssier C; Bailly C
Biochemistry; 1994 Aug; 33(33):9865-74. PubMed ID: 8060993
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, DNA binding, topoisomerase II inhibition and cytotoxicity of two guanidine-containing anthracene-9,10-diones.
Routier S; Bernier JL; Catteau JP; Riou JF; Bailly C
Anticancer Drug Des; 1998 Jul; 13(5):407-15. PubMed ID: 9702207
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of anthrapyrazoles derivatives as potential antitumor agents.
Wang J; Zhao H; Luo Z; Wang Z; Zhang Y; Zhao J
Med Chem; 2014; 10(8):772-7. PubMed ID: 24773347
[TBL] [Abstract][Full Text] [Related]
19. Antitumor potential of aza-bioisosterism in anthracenedione-based drugs.
Sissi C; Palumbo M
Curr Top Med Chem; 2004; 4(2):219-30. PubMed ID: 14754455
[TBL] [Abstract][Full Text] [Related]
20. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.
Capranico G; De Isabella P; Tinelli S; Bigioni M; Zunino F
Biochemistry; 1993 Mar; 32(12):3038-46. PubMed ID: 8384486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
